1. Zhai J., Yan H., Zhang J., Yan H., Ma J., Zhang S. (2025) A comprehensive analysis of adverse drug reactions in 2020-2023: case studies. Front. Pharmacol., 16, 1628347. DOI: 10.3389/fphar.2025.1628347
2. Bennett C.L., Hoque S., Olivieri N., Taylor M.A., Aboulafia D., Lubaczewski C., Bennett A.C., Vemula J., Schooley B., Witherspoon B.J., Godwin A.C., Ray P.S., Yarnold P.R., Ausdenmoore H.C., Fishman M., Herring G., Ventrone A., Aldaco J., Hrushesky W.J., Restaino J., Thomsen H.S., Yarnold P.R., Marx R., Migliorati C., Ruggiero S., Nabhan C., Carson K.R., McKoy J.M., Yang Y.T., Schoen M.W., Knopf K., Martin L., Sartor O., Rosen S., Smith W.K. (2020) Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): a qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 31, 100693. DOI: 10.1016/j.eclinm.2020.100693
3. Tan Y., Hu Y., Liu X., Yin Z., Chen X.-W., Liu M. (2016) Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation. Methods, 110, 14-25. DOI: 10.1016/j.ymeth.2016.07.023
4. Jenkinson S., Schmidt F., Rosenbrier Ribeiro L., Delaunois A., Valentin J.-P. (2020) A practical guide to secondary pharmacology in drug discovery. J. Pharmacol. Toxicol. Methods, 105, 106869. DOI: 10.1016/j.vascn.2020.106869
5. Dey S., Luo H., Fokoue A., Hu J., Zhang P. (2018) Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics, 19(Suppl 21), 476. DOI: 10.1186/s12859-018-2544-0
6. Scott C., Dodson A., Saulnier M., Snyder K., Racz R. (2022) Analysis of secondary pharmacology assays received by the US Food and Drug Administration. J. Pharmacol. Toxicol. Methods, 117, 107205. DOI: 10.1016/j.vascn.2022.107205
7. Guggina L.M., Choi A.W., Choi J.N. (2017) EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol. Ther., 5, 135-148. DOI: 10.1007/s40487-017-0050-6
8. Mascolo A., Rafaniello C., Sportiello L., Sessa M., Cimmaruta D., Rossi F., Capuano A. (2016) Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Safety, 39(5), 401-407. DOI: 10.1007/s40264-016-0399-8
9. Noguchi Y., Murayama A., Esaki H., Sugioka M., Koyama A., Tachi T., Teramachi H. (2021) Angioedema caused by drugs that prevent the degradation of vasoactive peptides: a pharmacovigilance database study. J. Clin. Med., 10(23), 5507. 8. DOI: 10.3390/jcm10235507
10. Савосина П.И., Дружиловский Д.С., Филимонов Д.А., Поройков В.В. (2025) Конструирование высокоспецифичных структурных фрагментов для фильтрации соединений с нежелательной активностью. Biomedical Chemistry: Research and Methods, 8(4), e00303. DOI: 10.18097/BMCRM00303
Savosina P.I., Druzhilovskiy D.S., Filimonov D.A., Poroikov V.V. (2025) Design of highly specific structural fragments for filtering compounds with undesirable activities. Biomedical Chemistry: Research and Methods, 8(4), e00303.
11. PubChem database. Table of Contents. Clinical trials. Retrieved November 2, 2025, from: https://pubchem.ncbi.nlm.nih.gov/classification/?hid=72&hnid=1856916&cache_uid_type=Compound&alias=PubChem%20Compound%20TOC:%20Clinical%20Trials.
12. United States Federal Register. Food and Drug Administration. Docket No. FDA-2024-N-3165. Retrieved November 24, 2025, from: https://www.federalregister.gov/d/2024-15371.
13. US Food and Drug Administration. FDA Drug Shortages. Saxagliptin Tablets. Retrieved November 24, 2025, from: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Saxagliptin+Tablets&st=d&tab=tabs-4&panels=0.
14. Swanson C.D., Akama-Garren E.H., Stein E.A., Petralia J.D., Ruiz P.J., Edalati A., Lindstrom T.M., Robinson W.H. (2012) Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. J. Immunol., 188(7), 3513-3521. DOI: 10.4049/jimmunol.1102693
15. Savosina P., Druzhilovskiy D., Filimonov D., Poroikov V. (2024) WWAD: the most comprehensive small molecule World Wide Approved Drug database of therapeutics. Front. Pharmacol., 15, 1473279. DOI: 10.3389/fphar.2024.1473279
16. Yang F., Takagaki Y., Yoshitomi Y., Ikeda T., Li J., Kitada M., Kumagai A., Kawakita E., Shi S., Kanasaki K., Koya D. (2019) Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res., 79(4), 735-746. DOI: 10.1158/0008-5472.CAN-18-0620
17. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Retrieved November 2, 2025, from: https://www.fda.gov/drugs/drug-safety-and-availability/ fda-drug-safety-communication-fda-warns-dpp-4-inhibitorstype- 2-diabetes-may-cause-severe-joint-pain.